MiNK Therapeutics, Inc. Common Stock
$11.59
$0.18 (+1.58%)
$11.31Day Range$11.68
Key Statistics
Market Cap
$58.23M
Shares Outstanding
5.1M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 15, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$11.47
Day High
$11.68
Day Low
$11.31
Volume
4.8K
VWAP
$11.54
Prev Close
$11.41
Transactions
--
Acc. Volume
--
About MiNK Therapeutics, Inc. Common Stock
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283615 employees149 FIFTH AVENUE, NEW YORK, NY, 10010212-994-8250IPO Oct 15, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001840229
- Composite FIGI
- BBG012J84VS3
- Share Class FIGI
- BBG012J84WM7
- Ticker Root
- INKT
- SIC Code
- 2836
About MiNK Therapeutics, Inc. Common Stock (INKT) Stock
MiNK Therapeutics, Inc. Common Stock (INKT) closed the 2026-09-16 session at $11.59, up 1.58% versus the previous close (+0.18). The stock opened at $11.47 and traded between $11.31 and $11.68 during that session. Session trading volume was 5K shares. The volume-weighted average price (VWAP) is $11.54.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
MiNK Therapeutics, Inc. Common Stock has a market capitalization of $58.2 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. INKT is listed on the XNAS exchange. The company employs approximately 15 people. MiNK Therapeutics, Inc. Common Stock is headquartered in NEW YORK, NY. The recorded listing date is 2021-10-15.
On this page you can find market INKT stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.